Welcome to our dedicated page for NovaBridge Biosciences news (Ticker: NBP), a resource for investors and traders seeking the latest updates and insights on NovaBridge Biosciences stock.
NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology platform company whose news flow centers on clinical data readouts, strategic collaborations, and corporate milestones. The company highlights a pipeline led by the bispecific antibodies givastomig and ragistomig, the anti-CD73 antibody uliledlimab, and the bifunctional biologic VIS-101.
News updates frequently cover oncology clinical trial results. For givastomig, NovaBridge has reported Phase 1b combination data in first-line HER2-negative metastatic gastric cancer, where the Claudin 18.2 x 4-1BB bispecific antibody is combined with nivolumab and chemotherapy. Releases describe objective response rates, progression-free survival measures, safety profiles, and biomarker analyses across CLDN18.2 and PD-L1 expression levels. For ragistomig, the company publishes Phase 1 monotherapy and dose expansion data in heavily pre-treated solid tumor patients, including comparisons of different dosing schedules and their safety and disease control rates.
Investors can also expect ophthalmology program updates through NovaBridge’s Visara subsidiary, particularly around VIS-101 in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Announcements have included leadership appointments at Visara and licensing arrangements with Everest Medicines for VIS-101 in Greater China and certain Asian markets.
Corporate and capital markets developments are another regular theme. NovaBridge has issued news on its transition from I-Mab to NovaBridge Biosciences, the change of its Nasdaq ticker to NBP, and its inclusion in the Nasdaq Biotech Index. The company also communicates its intention to pursue a dual listing on Nasdaq and the Hong Kong Stock Exchange.
By following the NBP news feed, readers can track clinical progress across multiple programs, updates on global partnerships, and key branding and listing milestones that shape NovaBridge’s evolution as a biotechnology platform.
NovaBridge (Nasdaq: NBP) appointed Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board on February 19, 2026, and named him to the Board's Research and Development Committee.
Dr. Cunningham is co-founder and executive chairman of Visara, brings 20+ years of biopharma leadership, prior roles at Blackstone and Clarus, and is an infectious and inflammatory eye disease specialist with over 450 co-authored publications.
NovaBridge (Nasdaq: NBP) dosed the first patient in a global, randomized Phase 2 study testing givastomig (CLDN18.2 x 4-1BB) plus nivolumab and mFOLFOX6 in 1L HER2-negative metastatic gastric cancer.
Phase 2 uses 8 mg/kg and 12 mg/kg dose arms, follows Phase 1b showing ORR 75% and mPFS 16.9 months, and targets top-line results in 2027. The company cites a $12 billion market opportunity by 2030.
NovaBridge (Nasdaq: NBP) announced that Executive Chairman Fu Wei intends to purchase up to $5,000,000 of the company’s American Depository Shares (ADSs) in open‑market transactions. The purchases began on January 15, 2026 and were ongoing as of January 20, 2026. The planned purchases are being executed via an entity controlled by Fu Wei, and the company stated it cannot guarantee the number of ADSs to be purchased or the time frame for purchases. The announcement referenced positive Phase 1b dose expansion data for givastomig in first‑line metastatic gastric cancer and framed the insider purchases as tied to confidence in the company’s clinical progress and strategy.
NovaBridge (Nasdaq: NBP) reported Phase 1b dose expansion results for givastomig (CLDN18.2 x 4-1BB) combined with nivolumab and mFOLFOX6 in 1L HER2-negative metastatic gastric cancer.
Key data: ORR 77% at 8 mg/kg and 73% at 12 mg/kg (efficacy evaluable n=26 each); median PFS 16.9 months at 8 mg/kg (median follow-up 10.7 months) while 12 mg/kg follow-up is shorter (6.8 months, median PFS 7.7 months, immature). Six-month PFS: 73% (8 mg/kg) and 91% (12 mg/kg). Combination tolerable; immune-related gastritis observed in 33% of patients and correlated with improved outcomes. Global randomized Phase 2 enrollment planned Q1 2026.
NovaBridge (Nasdaq: NBP) will ring the Nasdaq Opening Bell on Friday, January 2, 2026 at 9:15 AM ET, with Executive Chairman Fu Wei, CEO Sean Fu and members of management participating.
The company also announced inclusion in the Nasdaq Biotech Index (NBI), effective December 19, 2025, which the company says increases visibility and underscores its position as a global biotech platform focused on accelerating access to innovative medicines.
The bell-ringing ceremony will be held in Times Square and streamed live via Nasdaq’s bell-ringing webcast.
NovaBridge (Nasdaq: NBP) presented Phase 1 dose‑expansion data for ragistomig (4‑1BB × PD‑L1 bispecific) at ESMO‑IO on Dec 10, 2025. The 3 mg/kg every‑6‑weeks (Q6W) cohort (20 patients) showed comparable antitumor activity to 3 mg/kg every‑2‑weeks (Q2W) with a 58.8% disease control rate (DCR) vs 64.3% at Q2W and an objective response rate (ORR) of 11.8% vs 28.6% at Q2W (evaluable N=17 vs N=14).
Safety improved on Q6W: Grade ≥3 LFT elevation 5% vs 40%, TEAEs ≥Grade 3 were 50% vs 66.7%, no cytokine release syndrome reported, and no discontinuations due to TEAEs. Immunology data showed CD8+ effector/memory expansion with attenuated Treg increases. A 5 mg/kg Q6W cohort is enrolling.
NovaBridge (Nasdaq: NBP) announced that expanded Phase 1 dosing data for ragistomig (4-1BB x PD-L1 bispecific) will be presented in a poster at ESMO-IO on December 10, 2025. The company said the Q6W extended dosing interval met the study objective by delivering strong anti-tumor efficacy in PD-L1 non-responders while improving tolerability, including hepatic safety. Interim immunologic readouts showing CD8+ cell proliferation and memory T-cell activation will be included. The poster (Abstract #688) will be presented by Gerald Falchook, MD, at 5:30 PM GMT and supports planned progression to combination studies with partner ABL Bio.
NovaBridge (Nasdaq: NBP) subsidiary Visara appointed Cadmus C. Rich, MD, MBA as Chief Medical Officer and Carlos Quezada-Ruiz, MD, FASRS as Chair of its Scientific Advisory Board on Nov 20, 2025.
Visara said these hires strengthen clinical development for VIS-101, a bifunctional biologic targeting VEGF-A and ANG-2, and stated VIS-101 is expected to be Phase-3-ready in 2026. Management framed the appointments as validation of VIS-101’s opportunity and as contributors to completing Phase 2 and advancing registrational development.
NovaBridge (Nasdaq: NBP) said subsidiary Visara assigned its exclusive license for VIS-101 to Everest Medicines (HKEX: 1952) for development, manufacture and commercialization in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Everest will assume payment obligations under the assigned AskGene license and reimburse Visara for any upfront payment. VIS-101 is a bifunctional biologic targeting VEGF-A/ANG-2, completing a Phase 2 study in China and expected to be Phase-3-ready in 2026. NovaBridge also appointed Ian Woo, president and CFO of Everest Medicines, to its board.
The deal aims to leverage Everest’s regional clinical and commercialization expertise to accelerate VIS-101 development and patient access across Asia.
NovaBridge Biosciences (Nasdaq: NBP) announced it changed its corporate name from I‑Mab and will begin trading under the new ticker NBP at the open on October 30, 2025. Shareholder approval was granted on October 24, 2025 and no action is required by existing ADS holders. The company outlined a strategic shift to a global “hub‑and‑spoke” biotech platform, including a planned Hong Kong IPO and dual listings on Nasdaq and HKEX to broaden capital access.
Key program moves: the formation of subsidiary Visara and its acquisition of VIS‑101 (VEGF‑A/ANG2 bifunctional biologic); a ~$37M initial capital infusion into Visara; givastomig progressing toward a global randomized Phase 2 with first patient targeted in Q1 2026.